Ultragenyx EVP logs share grant and tax sale

Ultragenyx Pharmaceutical EVP & Chief Commercial Officer Erik Harris reported both an equity award and a related share sale.

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical EVP & Chief Commercial Officer Erik Harris reported both an equity award and a related share sale. On March 1, 2026, he acquired 11,643 shares of common stock at $0.00 per share from previously granted performance stock units that converted upon certification of performance metrics.

On March 2, 2026, he sold 10,539 shares of common stock at a weighted-average price of $22.80 per share to cover required tax withholdings tied to restricted stock unit vesting. After these transactions, he directly held 89,515 shares of common stock, plus additional RSUs subject to vesting conditions.

Insider Trade Summary

Net Seller: 10,539 shares

Net Sell 2 txns

Insider Harris Erik

Role EVP & Chief Commercial Officer

Sold 10,539 shs ($240K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,539	$22.80	$240K
Grant/Award	Common Stock	11,643	$0.00	$0.00

Holdings After Transaction: Common Stock — 89,515 shares (Direct)

Footnotes (5)

1. F1. Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics.
2. F2. Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range
4. F4. Includes a total of 556 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2025 and October 31, 2025.
5. F5. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Ultragenyx (RARE) executive Erik Harris report?

Erik Harris reported both an equity award and a share sale. He received 11,643 Ultragenyx common shares from performance stock units and sold 10,539 shares, with the sale specifically to cover tax withholdings related to restricted stock unit vesting.

How many Ultragenyx (RARE) shares did Erik Harris sell and at what price?

Erik Harris sold 10,539 Ultragenyx common shares at a weighted-average price of $22.80. The shares were sold in multiple transactions between $22.54 and $23.11 per share to satisfy required tax withholdings triggered by the vesting of restricted stock units.

What equity award did Ultragenyx (RARE) grant to Erik Harris in this Form 4?

Ultragenyx recorded an acquisition of 11,643 common shares by Erik Harris at $0.00 per share. These shares came from previously granted performance stock units that converted on March 1, 2026 after the company certified that the applicable performance metrics had been met.

Why did Ultragenyx (RARE) executive Erik Harris sell shares in this filing?

The filing states that Erik Harris sold 10,539 Ultragenyx shares to pay required tax withholdings. Those withholding obligations arose because his restricted stock units vested, and selling shares provided the cash needed to satisfy the associated tax liabilities.

How many Ultragenyx (RARE) shares does Erik Harris hold after these transactions?

After these transactions, Erik Harris directly holds 89,515 Ultragenyx common shares. This figure includes 556 shares acquired under the company’s Employee Stock Purchase Plan and previously reported shares underlying restricted stock units that remain subject to vesting conditions.

Were the Ultragenyx (RARE) share sales by Erik Harris open-market transactions?

Yes. The Form 4 describes the 10,539-share transaction as an open-market sale with code “S.” However, the footnotes clarify the purpose was to cover required tax withholdings due to restricted stock unit vesting, rather than a discretionary portfolio rebalancing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 07:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harris Erik

(Last) (First) (Middle)

60 LEVERONI COURT

(Street)

NOVATO CA 94949

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		11,643(1)	A	$0	99,498	D
Common Stock	03/02/2026		S		10,539(2)	D	$22.8(3)	89,515(4)(5)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics.

2. Represents shares sold to pay required tax withholdings due to the vesting of RSUs.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range

4. Includes a total of 556 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2025 and October 31, 2025.

5. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

	/s/ Karah Parschauer, attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.